Divergent Clinical and Immunologic Outcomes Based on STK11 Co-mutation Status in Resectable KRAS-Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade
Authors:
- Samuel RosnerSRSamuel Rosner
- Sydney ConnorSCSydney Connor
- Khaled SanberKSKhaled Sanber
- Marianna ZahurakMZMarianna Zahurak
- Tianbei ZhangTZTianbei Zhang
- Isha GurumurthyIGIsha Gurumurthy
- Zhen ZengZZZhen Zeng
- Brad PressonBPBrad Presson
- Dipika SinghDSDipika Singh
- Roni RayesRRRoni Rayes
- Lavanya SivapalanLSLavanya Sivapalan
- Gavin PereiraGPGavin Pereira
Open Access
- 15 November 2024
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (2) , 339-351
Abstract
Purpose: Co-mutations of the Kirsten rat sarcoma virus (KRAS) and serine/threonine kinase 11 (STK11) genes in advanced non–small cell lung cancer (NSCLC) are associated with immune checkpoint blockade (ICB) resistance. Although neoadjuvant chemoimmunotherapy is now a standard-of-care treatment for resectable NSCLC, the clinical and immunologic impacts of KRAS and STK11 co-mutations in this setting are unknown. Experimental Design: We evaluated and compared recurrence-free survival of resectable KRAS-mutated NSCLC tumors, with or without co-occurring STK11 mutations, treated with neoadjuvant ICB. Single-cell transcriptomics was performed on tumor-infiltrating T cells from seven KRASmut/STK11wt tumors and six KRAS and STK11 co-mutated (KRASmut/STK11mut) tumors. Results: Relative to KRASmut/STK11wt tumors, KRASmut/STK11mut exhibited significantly higher recurrence risk. Single-cell transcriptomics showed enhanced oxidative phosphorylation with evidence of decreased prostaglandin E2 signaling and increased IL-2 signaling in CD8+ tumor-infiltrating lymphocytes (TIL) from KRASmut/STK11mut tumors, a finding that was mirrored in KRASwt tumors that relapsed. TILs from KRASmut/STK11mut tumors expressed high levels of molecules associated with tumor residence, including CD39 and ZNF683 (HOBIT). Conclusions: These divergent T-cell transcriptional fates suggest that T-cell maintenance and residence may be detrimental to antitumor immunity in the context of neoadjuvant ICB for resectable NSCLC, regardless of KRAS mutation status. Our work provides a basis for future investigations into the mechanisms underpinning prostaglandin E2 signaling and IL-2 signaling as they relate to T-cell immunity to cancer and to divergent clinical outcomes in KRASmut/STK11mut NSCLC treated with neoadjuvant ICB.Keywords
All Related Versions
Funding Information
- Conquer Cancer Foundation
- LUNGevity Foundation
- Lung Cancer Foundation of America
- Mark Foundation For Cancer Research
- Swim Across America
- Bloomberg∼Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
- American Lung Association
- National Institutes of Health (R37CA251447)
- National Institutes of Health (P30CA008748)
- National Institutes of Health (P30CA006973)
This publication has 45 references indexed in Scilit:
- Neoadjuvant PD-1 Blockade in Resectable Lung CancerNew England Journal of Medicine, 2018
- T Cells in Nonlymphoid Tissues Give Rise to Lymph-Node-Resident Memory T CellsImmunity, 2018
- Metabolic Regulation of T Cell Longevity and Function in Tumor ImmunotherapyCell Metabolism, 2017
- STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor MicroenvironmentCancer Research, 2016
- RGC-32 is a novel regulator of the T-lymphocyte cell cycleExperimental and Molecular Pathology, 2015
- Targeted Next-Generation Sequencing of Cancer Genes in Advanced Stage Malignant Pleural Mesothelioma: A Retrospective StudyJournal of Thoracic Oncology, 2015
- Role of LKB1-CRTC1 on Glycosylated COX-2 and Response to COX-2 Inhibition in Lung CancerJNCI: Journal of the National Cancer Institute, 2014
- The developmental pathway for CD103+CD8+ tissue-resident memory T cells of skinNature Immunology, 2013
- Prostaglandin A2 Acts as a Transactivator for NOR1 (NR4A3) within the Nuclear Receptor SuperfamilyBiological and Pharmaceutical Bulletin, 2005
- CD63 as an Activation-Linked T Cell Costimulatory ElementThe Journal of Immunology, 2004